Next Generation Biotherapeutics Market to Grow with a CAGR of 12.07% through 2028
Increasing incidence of cancer and increasing R&D activities using NGS
technologies is expected to drive the Global Next Generation Biotherapeutics
Market growth in the forecast period, 2024-2028.
According to TechSci Research report, “Next
Generation Biotherapeutics Market – Global Industry Size, Share,
Trends, Competition Forecast & Opportunities, 2028”, the Global Next
Generation Biotherapeutics Market stood at USD 4.31 billion in 2022 and is
anticipated to grow with a CAGR of 12.07% in the forecast period, 2024-2028. The
global market for Next Generation Biotherapeutics is experiencing substantial
growth, attributed to technological advancements in this field and the
increasing prevalence of chronic diseases. Furthermore, the growth of the Next
Generation Biotherapeutics market is driven by the rise in healthcare
expenditure and the expansion of research and development activities.
Browse over XX market data Figures spread
through XX Pages and an in-depth TOC on "Global Next Generation Biotherapeutics Market.”
The market growth is primarily driven by the
increasing prevalence of chronic diseases like rheumatoid arthritis, inflammatory
bowel disorder, Crohn’s disease, and cancer. According to a research report by
Medscape in January 2022, the annual incidence rate of rheumatoid arthritis is
approximately 3 cases per 10,000 people, with a global prevalence rate of
around 1%. Additionally, the American Cancer Society reported in January 2021
that more than 1.9 million new cancer cases are expected to be diagnosed and
609,360 cancer-related deaths are projected in the United States in 2022. Next
Generation Biotherapeutics, known for their enhanced efficacy, improved safety,
and targeted treatment delivery, are widely used in the treatment of chronic
diseases and rare disorders, particularly cancer and autoimmune disorders.
Consequently, the market for next-generation antibodies is expected to expand
significantly due to the growing prevalence of chronic diseases and rare
disorders, with next-generation antibodies being the predominant therapy.
Prominent biotechnology and pharmaceutical companies
are increasingly investing in the development of therapeutic antibodies to
combat inflammatory diseases, cancer, and autoimmune disorders. For example, in
November 2022, Seagen announced the FDA approval of brentuximab vedotin
(ADCETRIS) for children with previously untreated high-risk Hodgkin lymphoma.
In the same month, ImmunoGen received accelerated approval from the FDA for
ELAHERE (mirvetuximab soravtansine-gynx) for the treatment of
platinum-resistant ovarian cancer in adults. Moreover, F-star Therapeutics
announced a license agreement with Takeda in July 2022, granting Takeda
exclusive rights to research, develop, and commercialize a bispecific
next-generation antibody targeting an immuno-oncology target. In March 2022,
Bayer revealed its plans to invest EUR 2 billion over the next three years to
expand its next-generation manufacturing capabilities.The global demand for Next
Generation Biotherapeutics is expected to grow significantly during the
forecast period, driven by their success in treating chronic conditions such as
cancer and autoimmune diseases. Scientific advancements have played a crucial
role in improving the effectiveness of antibody therapeutics. Additionally,
technological developments in this field and the increasing prevalence of
chronic diseases have contributed to substantial market growth. Furthermore,
the market expansion is fueled by rising healthcare expenditure and growing research
and development activities.
The rising prevalence of chronic disorders is another
significant factor driving the market for Next Generation Biotherapeutics. The
integration of technology to support research and development activities is
expected to further propel industry growth in the coming years. Many
governments are increasing funding and grants for research in the antibody
therapeutics market. Coupled with the growing healthcare spending in developed
and developing countries, this will drive demand growth during the forecast
period.
The Global Next Generation Biotherapeutics Market is
segmented into therapeutic area and technology, regional distribution, and
company.Based on technology, the Antibody-Drug Conjugates (ADC) segment is
projected to hold the largest market share in the Next Generation
Biotherapeutics market. ADCs represent a significant advancement in this field
as they combine the cytotoxic potential of chemotherapy with the favorable
properties of antibodies, resulting in highly specific and efficient
therapeutic options. ADC technology is predominantly used in the manufacturing
of Next Generation Biotherapeutics for cancer treatment. These therapies
involve linking an anti-cancer drug or therapeutic substance to an antibody or
antibody fragment.
Notably, sacituzumab govitecan, an antibody-drug
conjugate composed of a humanized anti-Trop-2 antibody conjugated to SN38, has
shown promising results as an effective and well-tolerated agent for metastatic
triple-negative breast cancer patients. This demonstrates the potential of ADCs
as a novel therapy. The growing demand for antibody-based cancer treatments,
coupled with the rising global incidence of breast cancer, advancements in
technology, and an increasing number of ADCs undergoing clinical trials, is
expected to drive the dominance of the antibody-drug conjugates (ADC) segment
in the market. Breast cancer currently ranks as the most common cancer
worldwide, accounting for 12.5% of all new annual cancer cases. In the United
States alone, an estimated 287,850 new cases of invasive breast cancer and
51,400 new cases of non-invasive (in situ) breast cancer are expected to be
diagnosed among women.
The rising demand for antibody therapeutics has led to
a surge in new drug approvals for ADCs. Various players in the industry are
actively engaged in the development of Next Generation Biotherapeutics using
ADC technology, employing different strategies. For example, Mersana
Therapeutics Inc. recently announced a partnership with Janssen Pharmaceutical
Companies to advance novel ADCs for the treatment of various cancers.
Similarly, ImmunoGen Inc. has entered into a multi-year research collaboration
with Oxford BioTherapeutics to develop innovative antibody-drug conjugates.
These collaborations are driving the growth of the segment and boosting the
revenue of the Next Generation Biotherapeutics market in the forecast period.
Based on region, North America segment is expected to
grow during the forecast period. North America is projected to maintain
its dominance in the overall Next Generation Biotherapeutics market during the
forecast period. This can be attributed to various factors, including the
increasing prevalence of autoimmune diseases, higher healthcare spending,
introduction of new products, and continuous growth in research and development
activities for the application of these therapeutics in treating different
disorders.
The rising incidence of chronic conditions like cancer
and asthma is also driving the Next Generation Biotherapeutics market.
According to a report published in September 2022 by the Asthma and Allergy
Foundation of America, approximately 25 million people in the United States
suffer from asthma each year, accounting for one in every thirteen Americans.
Moreover, as reported by Breast Cancer.Org in October 2022, as of January 2022,
there are over 3.8 million women in the U.S. with a history of breast cancer.
Hence, the increasing prevalence of chronic diseases in the region is contributing
to the growth of this sector.
Furthermore, the presence of prominent companies in
the region, expedited approval processes for Next Generation Biotherapeutics,
and access to reputable research centers all contribute to the expansion of the
market. According to an article published in November 2022 in Silicon Republic,
the U.S. FDA has approved its 100th monoclonal antibody therapeutic as of 2021.
For instance, in August 2022, AstraZeneca and Daiichi Sankyo's Enhertu
(trastuzumab deruxtecan) received approval in the United States for the
treatment of adult patients with unresectable or metastatic HER2-low breast
cancer who have received prior chemotherapy in the metastatic setting or
experienced disease recurrence during or within six months of completing
adjuvant chemotherapy. Additionally, in December 2022, Pyxis Oncology, Inc.
obtained clearance from the U.S. FDA to initiate Phase 1 clinical trials for
its Investigational New Drug (IND) application of PYX-201, a novel
antibody-drug conjugate (ADC) product candidate. The market is expected to
advance in the coming years, driven by multiple approvals and a pipeline of
several products. Moreover, the presence of advanced healthcare infrastructure
and well-established direct reimbursement policies is also anticipated to
contribute significantly to the market's revenue throughout the forecast
period.
Major companies operating in
Global Next Generation Biotherapeutics Market are:
- Xencor,
Inc.
- Regenxbio
& Neurimmune AG
- Takeda
Pharmaceutical Company Limited
- Pfizer,
Inc.
- AstraZeneca
Plc.
- F.
Hoffmann-La Roche AG
- Kyowa
Kirin Co., Ltd
- Seattle
Genetics, Inc
- ImmunoGen,
Inc
- Ono
Pharmaceuticals Co, Ltd
Download Free Sample Report
Customers can also request for 10%
free customization on this report.
“The future of the global Next Generation
Biotherapeutics Market looks promising, with significant advancements expected
in the fields of gene therapy, cell therapy, and immunotherapy. Technology
plays a critical role in this growth, with innovations in genetic sequencing
and bioinformatics predicting the creation of more targeted, effective
treatments. Additionally, the increasing prevalence of chronic diseases around
the world and a growing understanding of the human genome contribute to the
demand for these therapies. However, the market also faces challenges,
including complex regulatory landscapes and the high cost of therapies. Despite
these hurdles, the market is expected to witness substantial growth in the
coming years, transforming the landscape of healthcare and treatment.,” said
Mr. Karan Chechi, Research Director with TechSci Research, a research-based
management consulting firm.
“Next Generation Biotherapeutics Market Segmented By Therapeutic
Area (Oncology, Autoimmune/ Inflammatory Diseases), By Technology
(Antibody-Drug Conjugates, Bispecific Antibodies, Antibody Fragments,
Antibody-like Proteins, Others), By Region and Competition, Forecast & Opportunities, 2018-2028F”, has evaluated
the future growth potential of Global Next Generation Biotherapeutics Market
and provides statistics & information on market size, structure and future
market growth. The report intends to provide cutting-edge market intelligence
and help decision makers take sound investment decisions. Besides, the report
also identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Next Generation Biotherapeutics Market.
Contact
Mr.
Ken Mathews
708
Third Avenue,
Manhattan,
NY,
New
York – 10017
Tel:
+1-646-360-1656
Email:
[email protected]
Website:
www.techsciresearch.com